In a pooled analysis of SCD patients from two academic SCD centers in the USA, the median overall survival for Hb SS/Hb Sβ0-thalassemia/Hb SD and for Hb SC/HbSβ+-thalassemia was 48 and 55 years, respectively. Here, GSTM1 is linked to thalassemia.